STOCK TITAN
  1. Home
  2. News
  3. BETRF

BETTERLIFE PHARMA INC - BETRF STOCK NEWS

Welcome to our dedicated page for BETTERLIFE PHARMA news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on BETTERLIFE PHARMA stock.

BETTERLIFE PHARMA INC (BETRF) is a pharmaceutical company dedicated to developing innovative therapies for mental health disorders and neurological conditions. With a focus on research and development, the company is at the forefront of advancements in treatment options. BETRF's strong financial position and strategic partnerships enhance its ability to bring novel products to market.

News

BetterLife Advances BETR-001 IND-enabling Studies

Rhea-AI Summary

BetterLife Pharma Inc. announces progress in its IND-enabling studies for BETR-001, a non-hallucinogenic LSD derivative for mental disorders. The company has initiated GLP studies for metabolism and genotoxicity. BETR-001 has shown robust activity in animal models without hallucinogenic effects. BetterLife plans to file the IND application with the FDA by the end of 2024.

In March 2024, BetterLife disclosed its intention to conduct private placement offerings of Convertible Debentures to fund the development of BETR-001. The company closed a tranche of $30,000 10% Convertible Debentures with a two-year maturity to further advance BETR-001 development. Each Convertible Debenture is convertible into units of the company, including one common share and one share purchase warrant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
-
News

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Rhea-AI Summary
BetterLife Pharma Inc. (BETRF) will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, showcasing their focus on mental disorder treatments. The event will feature key executives discussing the company's initiatives and engaging with potential investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
News

BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Rhea-AI Summary
BetterLife Pharma Inc. announces participation in Bloom Burton Healthcare Investor Conference and resolution of a claim by issuing common shares valued at $19,687.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
conferences
News

BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

Rhea-AI Summary
BetterLife Pharma Inc. closes $1.168 million convertible debentures to advance BETR-001 development, a non-hallucinogenic derivative of LSD, targeting anxiety and depression disorders. FDA's breakthrough therapy designation for LSD in anxiety disorders validates BetterLife's research efforts. BETR-001 shows promising preclinical data with improved safety profile over LSD. Dr. Doroudian and Dr. Sangha, insiders of the company, subscribed for $100,000 each in the private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
News

BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

Rhea-AI Summary
BetterLife Pharma Inc. announces the development of 2-bromo-LSD for treating depression, with BETR-001 entering human trials in 2024. The company closes $65,000 in convertible debentures and plans further private placements for advancing BETR-001 and general working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
-
News

BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001

Rhea-AI Summary
BetterLife Pharma Inc. (BETR) closes $300,000 convertible debentures to advance development of BETR-001, a non-hallucinogenic derivative of LSD, for mental disorders treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.83%
Tags
none
News

BetterLife Announces Closing of a Private Placement

Rhea-AI Summary
BetterLife Pharma Inc. (BETR) has closed a non-brokered private placement, issuing 2,000,000 units at $0.10 per unit, generating $200,000 in gross proceeds. Each unit includes one common share and one warrant, with Dr. Ahmad Doroudian, the CEO, subscribing for 1,000,000 units. The private placement is exempt from certain regulatory requirements due to the company not being listed on a specified stock exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.87%
Tags
none
-
News

BetterLife Announces Extension of Warrants

Rhea-AI Summary
BetterLife Pharma Inc. (BETR) extends the expiry date of 6,386,298 outstanding share purchase warrants to December 2, 2025, with an original exercise price of $0.60. The warrants were granted pursuant to the exercise of the Company’s December 2020 private placement offering of special warrants. Previously issued warrant certificates remain valid and enforceable until the amended expiry date. Warrantholders may exercise their warrants by following the specified procedure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none
-
News

US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives

Rhea-AI Summary
BetterLife Pharma Inc. (BETR) announces the publication of its patent application for BETR-001 and LSD derivatives by the US Patent and Trademark Office. The application covers the development of non-hallucinogenic derivatives of LSD for the treatment of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches, and neuropathic pain. The company's efforts in developing novel therapies for mental disorders were also recognized in The Atlantic, highlighting the potential of the BETR-001 program. BETR-001 is projected to enter human trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
News

BetterLife Pharma to Host Investors Update Call on September 18, 2023

Rhea-AI Summary
BetterLife Pharma Inc. to host investor update Zoom call on September 18, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of BETTERLIFE PHARMA (BETRF)?

The current stock price of BETTERLIFE PHARMA (BETRF) is $0.07527 as of December 20, 2024.

What is the market cap of BETTERLIFE PHARMA (BETRF)?

The market cap of BETTERLIFE PHARMA (BETRF) is approximately 10.1M.

What is the core focus of BETTERLIFE PHARMA INC?

BETRF focuses on developing innovative therapies for mental health disorders and neurological conditions.

What sets BETRF apart from other pharmaceutical companies?

BETRF's strong emphasis on research and development, as well as strategic partnerships, distinguishes it in the industry.

How can I contact Investor Relations at BETRF?

You can reach out to David Melles, Investor Relations Manager, at David.Melles@blifepharma.com or call 1-778-887-1928.

Does BETRF have any recent achievements?

BETRF is known for its advancements in treatment options for mental health disorders and neurological conditions, reflecting its commitment to innovation.

What is the goal of BETTERLIFE PHARMA INC?

BETRF aims to improve the quality of life for individuals affected by mental health disorders through the development of cutting-edge therapies.

How can I stay informed about BETRF's latest developments?

Keep up to date with the latest news and updates from BETRF to stay informed about their progress in the pharmaceutical industry.

Is BETRF actively involved in research and development?

Yes, BETRF places a strong emphasis on R&D to drive innovation and bring novel products to the market.

What are some of BETRF's strategic partnerships?

BETRF collaborates with key partners to enhance its capabilities in developing and commercializing new therapies for mental health disorders.

Where is BETTERLIFE PHARMA INC headquartered?

BETRF is headquartered in a key location, allowing it to access top talent and resources in the pharmaceutical industry.

What is the vision of BETTERLIFE PHARMA INC?

BETRF envisions a future where individuals have access to advanced treatments that significantly improve their mental health and well-being.

Stock BETRF logo
BETTERLIFE PHARMA INC

OTC:BETRF

BETRF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BETRF Stock Data

10.12M
92.71M
27.53%
Biotechnology
Healthcare
Link
United States of America
Vancouver